NasdaqGM:TNDMMedical Equipment
Is FDA Pregnancy Clearance For Control-IQ+ Reshaping The Investment Case For Tandem Diabetes Care (TNDM)?
In late April 2026, Tandem Diabetes Care announced that the US FDA cleared its Control-IQ+ automated insulin delivery technology for use in pregnancies complicated by type 1 diabetes, covering both its t:slim X2 and Tandem Mobi systems.
The clearance, backed by CIRCUIT trial data showing several hours more daily time in the tight pregnancy glucose range versus standard therapy, further distinguishes Tandem’s automated insulin delivery portfolio in a clinically demanding setting.
We’ll now...